Uncategorized

Home 9 Category: Uncategorized ( Page 7 )

Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures

by aline | Dec 2, 2021 | Uncategorized

Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology

by aline | Nov 18, 2021 | Uncategorized

Advent France Biotechnology launches its second fund with a first close at €86M ($102M)

by aline | Sep 30, 2021 | Uncategorized

New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies

by aline | Sep 30, 2021 | Uncategorized

Advent France Biotechnology creates Thabor Therapeutics and finances its seed

by aline | Sep 13, 2021 | Uncategorized

Geoffroy de Ribains promoted to partner at Advent France Biotechnology

by aline | Jul 2, 2021 | Uncategorized

« Older Entries

Next Entries »

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Uncategorized

Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures

Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology

Advent France Biotechnology launches its second fund with a first close at €86M ($102M)

New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies

Advent France Biotechnology creates Thabor Therapeutics and finances its seed

Geoffroy de Ribains promoted to partner at Advent France Biotechnology

Recent Posts

Recent Comments

AdBio partners is a VC firm with a strong entrepreneurial spirit, specialized in early-stage investment in the most promising life sciences startups in Europe.

Menu

Contact

Follow Us